Skip to main content
Full access
Letters
Published Online: 1 January 2011

Rapid Weight Gain During Mirtazapine Treatment

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Mirtazapine is a novel antidepressant with a mechanism that enhances serotonergic and noradrenergic neurotransmission by blocking presynaptic alpha-2 adrenergic receptors and postsynaptic serotonin 5HT2 and 5HT3 receptors.1 The most frequently reported side effects of mirtazapine are transient sedation and weight gain associated with an increased appetite, due to its effects on 5HT2C and histaminergic (H1) receptors. Also, the drug can be effective in the treatment of anorexia nervosa and in cancer patients with nausea symptoms.2,3 In addition, diabetic ketoacidosis secondary to mirtazapine-induced weight gain has been reported.4 Herein, we report the case of a patient with major depressive disorder who rapidly gained 6.5 kg after administration of 30 mg of mirtazapine in 1 week.

Case Report

A 19-year-old Taiwanese man was admitted for psychiatric inpatient treatment because of major depressive disorder. The patient had presented the characteristic symptoms of depressed mood, loss of interest, anorexia, insomnia, and feelings of worthlessness in the preceding 2 months. He had been healthy in the past, without systemic disease such as metabolic disease. Initial laboratory studies revealed random blood glucose, 73 mg/dl (reference range: 70–105 mg/dl), and the thyroid function examination results were all within the normal range. He weighed 80.5 kg and scored 28 on the 17-item Hamilton Depression Rating Scale (Ham-D) on the first hospital day. Initially, he was treated with paroxetine, 20 mg/day, and zolpidem, 10 mg/night, for 14 days. His symptoms of depressed mood, anorexia, and marked insomnia were little improved. Also, he lost 4 kgs in 14 days. After this, treatment with paroxetine was discontinued, and mirtazapine, 30 mg, was prescribed at night. The patient's mood improved, but he also experienced intermittent headaches, increased appetite, and weight gain—6.5 kgs in 1 week. His Ham-D total score improved to 7 in that same week of mirtazapine therapy.

Discussion

Drug-induced weight gain is a serious problem with most psychotropic drugs, and it may be associated with health risks such as metabolic syndrome, cardiovascular disease, and type 2 diabetes. Weight gain associated with mirtazapine treatment has been reported and may be accounted for by its effects on 5HT2C and H1 receptors. The patient's rapid weight gain of 6.5 kg in 1 week of mirtazapine therapy is much faster than has been reported in the literature. Meanwhile, a significant improvement in the Ham-D total score was noted during this period. The possible mechanism of the initial weight gain associated with mirtazapine could be a direct effect due to the antihistaminic (H1) effects or early antidepressant action to improve appetite. In the future, it would be of interest to undertake a study of potential differential effects of mirtazapine versus other antidepressants, such as selective serotonin reuptake inhibitors, in the relationships of weight gain and Ham-D total score.

References

1.
de Boer T: The pharmacological profile of mirtazapine. J Clin Psychiatry 1995; 57(suppl 4):19–26
2.
Hrdlicka M, Beranova I, Zamecnikova R, et al.: Mirtazapine in the treatment of adolescent anorexia nervosa: case-control study. Eur Child Adolesc Psychiatry 2008; 17:187–189
3.
Kim SW, Shin IS, Kim JM, et al.: Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008; 62:75–83
4.
Fisfalen ME, Hsiung RC: Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003; 160:797

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E7
PubMed: 21304130

History

Published online: 1 January 2011
Published in print: Winter 2011

Authors

Affiliations

Hsiu-Wen Chiu, R.N.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xin-Min Rd., Beitou District, Taipei, Taiwan
Tien-Chun Li, M.D.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xin-Min Rd., Beitou District, Taipei, Taiwan

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share